An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. reported a significant increase in revenue for 2024, driven by strong sales of its key products, telitacicept and disitamab vedotin. The company has made notable advancements in its product pipeline, including FDA fast track designation for telitacicept for primary Sjögren’s Syndrome and achieving primary endpoints in clinical trials for generalized myasthenia gravis. Disitamab vedotin also showed promising results in various cancer treatments, enhancing RemeGen’s position in the biopharmaceutical industry.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapies for autoimmune diseases and cancer. The company is known for its products telitacicept and disitamab vedotin, which target autoimmune conditions and tumors, respectively.
YTD Price Performance: 39.93%
Average Trading Volume: 3,243,412
Technical Sentiment Signal: Hold
Current Market Cap: HK$17.59B
For an in-depth examination of 9995 stock, go to TipRanks’ Stock Analysis page.